Search
for
Sort by
Research
780-810 / 1000+ resultsresearch Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib
research The Future of Systemic Lupus Erythematosus Treatment: The Promise of Selective Immunotherapies, Anifrolumab and Belimumab, Compared to Blanket Immunosuppressives
Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.
research Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib
Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
research Protein-losing Enteropathy Exacerbated with the Appearance of Symptoms of Systemic Lupus Erythematosus.
Protein-losing enteropathy worsened with lupus symptoms but improved with prednisolone.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Oral Presentations
The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.
research The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata
Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
Ruxolitinib cream may help treat severe hair loss in children.
research Serum level of vitamin D in patients with alopecia areata
Alopecia areata patients have lower vitamin D levels than healthy individuals.
research LETTERS TO THE EDITOR
Careful management of blood thinners is crucial for lupus patients with APS.
research Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders
Apremilast may be a promising long-term treatment for hidradenitis suppurativa.
research 43755 Rapid Reduction and Strict Complete Response in Itch With Oral Difelikefalin in Subjects With Notalgia Paresthetica and Moderate-to-Severe Pruritus
Oral difelikefalin significantly reduces itch in notalgia paresthetica.
research Autoimmunità e Covid-19: uno studio prospettico monocentrico di follow-up
Six months after COVID-19, most patients still had autoantibodies.
research Alopecia areata as another immune‐mediated disease developed in patients treated with tumour necrosis factor‐α blocker agents
Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.
research Hair and nail adverse events during treatment with target therapies for metastatic melanoma
People with certain allergic conditions or higher white blood cell counts have more severe hair loss, and treating hair and nail side effects early in melanoma therapy can improve quality of life.
research Impaired responses of peripheral blood mononuclear cells to T-cell stimulants in alopecia areata patients with a poor response to topical immunotherapy
Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.
research Interleukin-10-deficient Mice Are Less Susceptible to the Induction of Alopecia Areata
IL-10 may worsen alopecia areata instead of helping it.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research A CLINICAL STUDY OF ALOPECIA AREATA AND TO EVALUAT E OF THE EFFICACY OF 0.03% TOPICAL TACROLIMUS IN ITS TREATMENT
Topical tacrolimus is effective and safe for treating alopecia areata.
research Diagnostic challenges in determining alopecia areata
Diagnosing alopecia areata is challenging and requires careful examination and various tests to distinguish it from other hair loss types.
research Table 1_Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study.docx
Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.
research Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Heterogeneity in the genetic alterations and in the clinical presentation of acrodermatitis enteropathic: Case report and review of the literature
AE can have varied symptoms and genetic causes, but zinc therapy helps.
research Immunohistochemical localization of tgf-β in alopecia areata
research Alopecia Universalis Successfully Treated With Adalimumab
A woman with severe hair loss was successfully treated with the drug adalimumab.
research Evaluation of the Efficacy of Excimer Light 308 nm Wavelength Versus Low Level Laser in Treatment of Alopecia Areata
Excimer light therapy is more effective than low level laser therapy for treating alopecia areata.
research Vitiliginous lesions during contact immunotherapy for alopecia in a patient with autoimmune thyroiditis
Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.